Full-Time

Computational Biologist

Cellularization

Posted on 8/21/2026

United Therapeutics Corporation

United Therapeutics Corporation

Biotech company develops PAH therapies

Compensation Overview

$127.5k - $150k/yr

Silver Spring, MD, USA

In Person

At least four days per week on the Silver Spring campus.

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Python
R
Machine Learning
Julia

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Requirements
  • A Master’s degree in biomedical engineering, computational biology, applied mathematics, or a related field, plus 6 or more years of industry experience developing computational models of biological systems; or a PhD plus 2 or more years of such industry experience. Postdoctoral experience at a pharmaceutical or biotechnology company is acceptable.
  • Expertise in one or more modeling frameworks for cell-level behavior, such as agent-based models and cellular Potts models.
  • Expertise in numerical methods relevant to modeling and simulation, including solving systems of ordinary and/or partial differential equations, optimization, and Monte Carlo methods.
  • Fluency in one or more scientific programming languages, such as Python, R, or Julia.
  • Experience with cell-based modeling and simulation software packages, such as Morpheus and CompuCell3D.
  • Knowledge of molecular and cellular biology and drug development.
  • Ability to communicate effectively with technical and non-technical audiences, demonstrated by presentations and publications.
Responsibilities
  • Develop mathematical models of cellular processes in the lung, including cell division, migration, and adhesion, modulated by the mechanical and chemical environment, using published models and in-house extensions to analyze experimental data from cellularization of 3D-printed scaffolds.
  • Establish an iterative experimental-design cycle based on hypotheses generated by mathematical models to support the development of new cellularization approaches.
  • Implement model-qualification procedures to evaluate the impact of uncertainty and variability on model output and the resulting impact on experimental design.
  • Collaborate with computational biologists and engineers to integrate cell-based models into large multiscale models spanning organ-level to molecular-level processes.
  • Partner with internal and external laboratories to understand experimental scientists’ needs and coordinate the generation of experimental data for model training and validation.
  • Communicate results through interactive visualizations and presentations at internal and external meetings, and publish in peer-reviewed journals.
  • Perform other duties as assigned.
Desired Qualifications
  • A Doctor of Philosophy degree in biomedical engineering, computational biology, applied mathematics, or a related field.
  • Familiarity with quantitative systems pharmacology and other modeling and simulation applications in pharmaceutical drug discovery and development.
  • Skill in statistical and machine learning methods.
  • Knowledge of pulmonary physiology.
United Therapeutics Corporation

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved LungFX on June 29, 2026, with services targeted for 2027.
  • Second-quarter 2026 net income rose to $333 million despite softer revenue.
  • United Therapeutics bought Thymmune for $140 million, expanding transplant-tolerance programs.

What critics are saying

  • Tyvaso net sales fell in Q2 2026 as Yutrepia launches intensified.
  • Liquidia and Boehringer lawsuits threaten Treprostinil revenues and sales execution through 2027.
  • Tyvaso concentration makes a bad PAH cycle or trial failure existential.

What makes United Therapeutics Corporation unique

  • LungFX approval makes United Therapeutics first in centralized EVLP.
  • Thymmune acquisition deepens its organ-tolerance and regenerative-medicine moat.
  • Cash-rich rare-disease franchise funds organ manufacturing and xenotransplantation bets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Holidays

Paid Vacation

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Professional Certification Support

Tuition Reimbursement

Stock Options

Company Equity

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Sabbatical Leave

Hybrid Work Options

Remote Work Options

Flexible Work Hours

ParentAL Leave

Company News

Investor's Business Daily
Aug 12th, 2026
Liquidia drops 4% despite $170M Yutrepia sales beat, misses earnings by 2 cents

Liquidia shares fell more than 4% on Wednesday despite the company's lung disease drug Yutrepia beating second-quarter sales expectations. The treatment generated $170.4 million in sales, growing 31% and surpassing forecasts of $166.4 million. However, the company posted earnings of 74 cents per share, slightly missing expectations of 76 cents. Yutrepia, which launched in June 2025, competes with United Therapeutics' Tyvaso in treating high blood pressure in the lungs. Since launch, Liquidia has received approximately 5,900 new patient prescriptions, with more than 5,000 patients starting treatment. Over 1,100 physicians now prescribe the drug. Liquidia stock has gained 155% year-to-date and ranks second on the IBD 50 list of elite growth stocks.

Yahoo Finance
Aug 7th, 2026
United Therapeutics reports $333M net income and $7.27 EPS as ralinepag files for FDA approval

United Therapeutics reported second-quarter 2026 results showing sales of $783.3 million, a slight year-on-year decline, whilst net income rose to $333 million and diluted earnings per share increased to $7.27. The company continued share repurchases under its $1.50 billion buyback programme, retiring 5.84% of shares. The biotech firm also published positive phase 3 ADVANCE OUTCOMES data for investigational pulmonary arterial hypertension therapy ralinepag and filed with the FDA. The stronger earnings per share partly reflects the shrinking share count from buybacks. Analysts remain divided on the company's future, with some projecting only 1.2% annual revenue growth and $1.4 billion earnings by 2029, citing concerns about its concentrated portfolio of pulmonary drugs and regulatory uncertainties.

Yahoo Finance
Jul 23rd, 2026
United Therapeutics appoints ex-National Academy of Medicine president Victor Dzau to board

United Therapeutics Corporation has appointed Victor Dzau to its board of directors, effective 22 July 2026. Dr Dzau recently completed a 12-year term as president of the National Academy of Medicine and previously served as chancellor for health affairs at Duke University and president of the Duke University Health System. Dr Dzau is recognised globally as a physician-scientist whose research laid the foundation for ACE inhibitors. He pioneered gene therapy for vascular disease and currently studies cardiac regeneration. Martine Rothblatt, chairperson and chief executive officer of United Therapeutics, said Dr Dzau is uniquely capable of guiding the company in its mission of developing transplantable organs and organ alternatives for patients with end-stage organ failure.

Yahoo Finance
Jul 11th, 2026
United Therapeutics wins FDA approval for LungFX device amid questions over valuation

United Therapeutics is under scrutiny after the US FDA approved its LungFX device for centralised ex vivo lung perfusion. The stock has shown strong momentum, with a year-to-date return of 10.13% and a one-year total shareholder return of 85.12%, though short-term prices have eased slightly. The company closed at $547.06, against a narrative fair value of $665.23, suggesting an 18% undervaluation. The valuation gap depends on whether LungFX, Tyvaso, and the broader pulmonary and organ platforms can drive future earnings. United Therapeutics' pipeline includes studies in progressive fibrosis, next-generation delivery platforms, and organ manufacturing technologies. However, the company faces risks from potential trial setbacks and drug pricing reforms that could impact profitability and cash flows.

Yahoo Finance
Jul 8th, 2026
United Therapeutics acquires Thymmune for $140M to advance organ transplant innovation

United Therapeutics Corporation acquired Thymmune Therapeutics for $140 million in cash, with potential additional earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031. Thymmune develops regenerative thymic cell therapies using human-induced pluripotent stem cells. The acquisition expands United Therapeutics' organ transplantation capabilities. The company focuses on treating life-threatening diseases, including pulmonary arterial hypertension, whilst addressing the global organ shortage through xenotransplantation, 3D bioprinting, and ex vivo lung perfusion technologies. Separately, the FDA granted premarket approval for LungFX, which Leerink Partners described as a regulatory advancement supporting the company's long-term organ manufacturing strategy. Leerink maintains an Outperform rating on United Therapeutics shares.